Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2020 May;94:49-52.
doi: 10.1016/j.ijid.2020.03.065. Epub 2020 Apr 3.

Diagnostic Value and Dynamic Variance of Serum Antibody in Coronavirus Disease 2019

Free PMC article

Diagnostic Value and Dynamic Variance of Serum Antibody in Coronavirus Disease 2019

Yujiao Jin et al. Int J Infect Dis. .
Free PMC article


Objective: To investigate the diagnostic value of serological testing and dynamic variance of serum antibody in coronavirus disease 2019 (COVID-19).

Methods: This study retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with a suspected infection, in whom the disease was eventually excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis.

Results: Compared to molecular detection, the sensitivities of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificities were 100% and 90.9%, respectively.In the COVID-19 group, the IgM-positive rate increased slightly at first and then decreased over time; in contrast, the IgG-positive rate increased to 100% and was higher than IgM at all times. The IgM-positive rate and titer were not significantly different before and after conversion to virus-negative. The IgG-positive rate was up to 90% and not significantly different before and after conversion to virus-negative. However, the median IgG titer after conversion to virus-negative was double that before, and the difference was significant.

Conclusions: Viral serological testing is an effective means of diagnosis for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than those of IgM in COVID-19.

Keywords: COVID-19; Diagnosis; Immunoglobulin G; Immunoglobulin M; SARS-CoV-2; Serological test.


Figure 1
Figure 1
Serological test positive rates and SARS-CoV-2 viral load at different intervals: (A) days from laboratory confirmation to serological testing; (B) days from symptom onset to serological testing.

Similar articles

See all similar articles

Cited by 1 article


    1. Al Johani S., Hajeer A.H. MERS-CoV diagnosis: an update. J Infect Public Health. 2016;9(3):216–219. doi: 10.1016/j.jiph.2016.04.005. - DOI - PMC - PubMed
    1. Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020 doi: 10.1016/j.micinf.2020.01.004. S1286-4579(20)30026-5. - DOI - PMC - PubMed
    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Pang J., Wang M.X., Ang I.Y.H., Tan S.H.X., Lewis R.F., Chen J.I. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020;9(3):E623. doi: 10.3390/jcm9030623. - DOI - PMC - PubMed

Supplementary concepts